All In Biotech

Drug Trial Radar · NCT05494918

First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors

A Phase I, Multi-center, Open-label, Dose Escalation, First-In-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of JSKN003 in Subjects With Advanced or Metastatic Solid Malignant Tumors

Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

Sep 2, 2022

Primary completion

Apr 15, 2025

Study completion Apr 15, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter, first-in-human, Phase I, dose escalation study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of JSKN003 in subjects with advanced inoperable or metastatic solid malignant tumors that are expected to be HER2 expression.

Conditions

  • Advanced Solid Tumors
  • Metastatic Solid Tumors

Interventions

  • JSKN003Drug

    JSKN003 is to be administered via intravenous (IV) dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTDTime frame: Postdose of last participant up to 1 year
  2. Preliminary RDE/RP2DTime frame: Postdose of last participant up to 1 year
  3. DLTsTime frame: Baseline up to 21 days after the first dose
  4. Adverse EventsTime frame: Baseline up to 30 days after the last dose of study drug, up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Breast Cancer Research Centre

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.